Quantcast

Global Personalized Medicines Industry

August 20, 2014



LONDON, Aug. 20, 2014 /PRNewswire/ — Reportbuyer.com has added a new market research report:

Global Personalized Medicines Industry

https://www.reportbuyer.com/product/2116899/Global-Personalized-Medicines-Industry.html

This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Product Segments: Targeted Therapeutics, and Tests & Lab Services. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2011 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 85 companies including many key and niche players such as –

Abbott Molecular, Inc.
Affymetrix, Inc.
AstraZeneca plc
Bayer HealthCare Pharmaceuticals
Beckman Coulter Genomics




I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Personalized Medicine I-3


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
Prelude II-1
Developing Countries Drive Growth II-2
Personalized Medicines Slowly Gaining Ground II-2
Personalized Medicine and Its Impact on Patient Care II-3
Table 1: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population (includes
corresponding Graph/Chart) II-4
Is Emergence of Personalized Medicine Signaling the End of
Blockbusters? II-4
List of Select Approved Personalized Medicines II-5

2. MARKET GROWTH DRIVERS AND RESTRAINTS II-6
Growth Drivers in a Gist II-6
Key Market Restraints II-6
Increasing Incidence and Prevalence of CDDs: A Major Growth
Driver II-6
Ballooning Global Population Offers Significant Growth
Opportunities II-7
Table 2: Top 25 Countries Worldwide in Terms of Population:
2010 & 2013 (includes corresponding Graph/Chart) II-8
Aging Global Population Drives Personalized Medicines II-9
Table 3: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-10
Table 4: Over-65 Years Population as a % of Total Population
(2010 & 2020P) (includes corresponding Graph/Chart) II-11
Table 5: Elderly Population (65+ Years) as a % of Total
Population (2000 & 2025) (includes corresponding Graph/Chart) II-11

Table 6: Life Expectancy at Birth for Select Countries (2012)
(includes corresponding Graph/Chart) II-12

Table 7: Percentage of Population Aged 65 and Above in EU-27
Countries, the US and Japan (1960-2030) (includes
corresponding Graph/Chart) II-13

Table 8: Life Expectancy Rates at Birth by Geographic Region
(1990 & 2011) (includes corresponding Graph/Chart) II-14
Increasing Healthcare Spending in Emerging Markets II-14
Table 9: Healthcare Spending as % of GDP in Select Countries
(2011) (includes corresponding Graph/Chart) II-15
Technological Advancements and Consumer Push to Drive
Personalized Medicine II-15
Economic Uncertainty Affects Spending on Healthcare Services II-15

3. PERSONALIZED MEDICINE – MARKET TRENDS & CHALLENGES II-17
Changing Patients’ Trends Drive Personalized Medicine II-17
Adverse Drug Reactions of Prescription Drugs Drive
Personalized Medicine Market II-17
List of Top 10 Drugs with Adverse Drug Reactions II-17
Genomics to Dictate Advancement of Personalized Medicines II-18
Investors’ Interest Personalized Medicines Gathers Steam II-18
Differentiation – The Key Aspect of Personalized Medicines to
Draw Investors II-18
Growing Investments in Sequencing Segment Drives Personalized
Medicines Market II-19
Companion Diagnostics Make Way for Personalized Medicine II-19
Select Popular Drugs with Companion Diagnostics II-20
Biomarkers as Companion Diagnostics II-20
Personalized Medicines Helps Reducing R&D Costs II-21
Personalized Medicine – A Corporate Growth Strategy II-21
Development Pipeline Reveals Promising Picture for
Personalized Medicine II-21
Advancements in Biomedical Imaging to Enhance Personalized
Medicines II-22
Increasing Use of Personalized Medicines Drives Genetic Testing II-22
Genetic Testing: The Rapidly Growing Segment of Molecular
Diagnostics Market II-22
Next-Generation Sequencing – A Giant Leap in Genome Sequencing II-23
Single Nucleotide Polymorphism (SNP) – Making Advancements in
Personalized Medicine II-23
Personalized Medicine Industry – Inundated with Data II-23
Challenges for Personalized Medicine II-24
Lack of Clinically Useful Diagnostic Tests – Growth Dampener II-24
Economics of Personalized Medicine II-24
Adoption of Personalized Medicines – A Peek into Developed and
Developing Economies II-25
Personalized Medicines Trigger Competition in the Market II-25

4. ONCOLOGY: A MAJOR PERSONALIZED MEDICINE MARKET II-27
Oncology – A Key Market for Personalized Medicine II-27
Diagnosed Cases of Cancer on the Rise II-27
Table 10: Global Cancer Incidence by Region: 2012 (includes
corresponding Graph/Chart) II-27

Table 11: Cancer Incidence in Developed Nations by Site: 2012
(includes corresponding Graph/Chart) II-28
World Cancer Statistics: Incidence and Mortality Data II-29
Table 12: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America & the Caribbean, and Africa (includes corresponding
Graph/Chart) II-29

Table 13: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer-Related Deaths (in Thousands)
for Asia-Oceania, Europe, North America, Latin America & the
Caribbean, and Africa (includes corresponding Graph/Chart) II-30

Table 14: New Cancer Cases in the World by Affected Site
(2012) (In Thousands) (includes corresponding Graph/Chart) II-31

Table 15: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung &
Bronchus, Prostate, Colorectal and Liver Cancers (includes
corresponding Graph/Chart) II-31

Table 16: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung & Bronchus and Liver Cancers (includes
corresponding Graph/Chart) II-32

Table 17: Global Cancer Mortality in Men for Select Cancers
(2012): Number of Deaths in Thousands for Lung & Bronchus,
Liver, Colorectal and Prostate Cancers (includes
corresponding Graph/Chart) II-32

Table 18: Global Cancer Mortality in Women for Select Cancers
(2012): Number of Deaths in Thousands for Breast, Lung &
Bronchus, Colorectal and Liver (includes corresponding
Graph/Chart) II-33
Cancer Prone Sites based on Age II-33
Growing Cancer Cases in Developing Countries Bodes Well for
the Personalized Medicine Market II-33
Growing Importance of Personalized Drugs for Cancer Treatment II-34
Global Cancer Biomarkers Market to Exhibit Growth II-34
Few FDA Approved Predictive Biomarkers by Disease Area II-34
Challenges for Adoption of Personalized Medicine in Cancer
Treatment II-35

5. SELECT TECHNOLOGICAL ADVANCEMENTS II-36
NanoVelcro Chip Device – Enhanced to Personalize Treatment for
Prostate Cancer II-36
Development of New Cancer Treatment Method for Personalized
Cancer Therapy II-36
Gene Therapy using a Pill for Treating Cancer II-36
New Ways of Offering Personalized Cancer Treatments II-37
Theranostic Imaging – Developed for Offering Personalized
Cancer Medicine II-37
New Personalized Treatment Approach Prolongs the Life of Lung
Cancer Patients II-37

6. PRODUCT OVERVIEW II-38
Personalized Medicine II-38
Benefits of Personalized Medicines II-38
Few Applications of Personalized Medicine II-38
Colorectal Cancer II-38
Blood Clots II-38
Breast Cancer II-39
Diagnostics in Personalized Medicine II-39
Genetic Tests II-39
Companion Diagnostics II-39
Genetic Testing II-40
Types of Genetic Testing II-40
Prenatal Diagnosis II-40
Cancer Testing II-40
Carrier Identification II-41
Newborn Screening II-41
Predictive Testing II-41
Pre-Symptomatic Testing II-41
Cytogenetic Tests II-41
Table 19: Costs of Select Genetic Tests II-42
Proteomics: A Critical Drug Discovery Tool II-42
Proteomics and Genomics: A Comparison II-43

7. PRODUCT INTRODUCTIONS AND APPROVALS II-44
NMTC Launches Expanded Personalized Medicine Panel Created on
Luminex’s xMAP Technology II-44
Dako to Introduce New Antibody to Diagnose Breast Cancer II-44
bioMérieux’s New Generation VIDAS® 3 Obtains CE Marking II-44
GSK’s Two New Single-Agent Oral Oncology Treatments Receive
FDA Approval II-44
Dako Obtains FDA Approval for Two Companion Diagnostic Assays
for Genentech’s Kadcyla II-44
Genentech Receives FDA Approval for Kadcyla Drug II-44
Dako’s FISH Assay for Cancer Diagnostics Obtains FDA Approval II-44
Luminex Receives US FDA Approval for MAGPIX® Instrument with
xTAG GPP II-45
QIAGEN Obtains FDA Approval for Marketing therascreen® KRAS
RGQ PCR Kit II-45
Roche Gains Approval from EMA for PERJETA II-45
OGT Unveils SureSeq(TM) Solid Tumor Panel Sequencing Service II-45
Abbott Launches Hepatitis C Virus Genotyping Test II-45
Luminex Obtains CE Marking for Neonatal Screening Systems II-45
IRIS International Launches NADiA® ProsVue(TM) Prognostic Test
for Cancer II-45
Lab21 Launches Novel Companion Diagnostic Service for Lung Cancer II-45
Lab21 to Offer FDA approved Companion Diagnostic Test II-46
Rosetta Genomics Obtains Approval from New York State
Department of Health for miRview® Lung Assay II-46
Merck Serono Receives Approval for Erbitux® for use in Neck
and Head Cancer II-46
Affymetrix Obtains Approval from China’s SFDA for GeneChip®
System 3000Dx v.2 II-46
Dako Obtains FDA Approval for Hercep Test(TM) and HERFISH pharma
Dx(TM) kit II-46
Roche Obtains Approval of Perjeta(TM) by USFDA II-46
NeoGenomics Introduces NeoTYPE(TM) Prognostic Panel II-46

8. RECENT INDUSTRY ACTIVITY II-47
Cancer Genetics and Mayo Clinic Establish JV II-47
QIAGEN and Eli Lilly Sign Master Collaboration Agreement II-47
Ignyta Takes Over Actagene Oncology II-47
Lab21 Divests Laboratory Business to Reedy Acquisitions II-47
Mayo Clinic Enters into Strategic Partnership with Silicon
Valley Biosystems II-47
Bristol Myers Squibb to Collaborate with Adaptive Biotechnologies II-47
Government of Québec Invests in Personalized Medicine
Partnership for Cancer II-47
Millennium Pharmaceuticals and Worldwide Innovative Network
Consortium Ink Collaboration Agreement II-48
Affymetrix and UK Biobank Ink Contract II-48
Bayer and Seattle Genetics Enter into Novel ADC Collaboration II-48
Lab21 Joins Hands with IntegraGen to Develop Novel Colorectal
Cancer Diagnosis II-48
Macrogen Establishes MCL II-48
INVENT and Heliant Co-Invest in Sanguine BioSciences II-48
Dako and Eli Lilly Enter into Partnership for Companion
Diagnostic Tests Development II-48
Geisinger to Enter into an Alliance with Indivumed II-48
Deloitte Takes Over Recombinant Data II-49
Thermo Fisher Scientific Renews Partnership with bioMérieux II-49
QIAGEN Sign Agreements to Acquire Global Rights for Two
Biomarkers II-49
Selventa to Build Disease Models for Johnson & Johnson II-49
Quintiles Takes Over Expression Analysis II-49
Mckesson Acquires CDS Oncology Assets from Proventys II-49
Horizon Partners with H3 Biomedicine to Develop Target Groups
for Cancer Drugs II-49
Abbott to Collaborate with Merck for FISH-based Diagnostic
Test Evaluation II-49
Bayer and QIAGEN Sign Strategic Partnership for Companion
Diagnostic Tests Development II-50
Life Technologies Signs a License and Supply Contract with VelaDx II-50
IDBS Announces Deployment of ORIS by King’s Health Partners II-50
PGXL Laboratories Inks Multi-Year Distribution Partnership
Agreement with Essential Molecular Testing II-50
Uniquest Inks Memorandum of Understanding with Aquavit
Pharmaceuticals II-50
Agilent Technologies Acquires Dako II-50
IRIS International Signs Merger Agreement with Danaher II-50
Lab21 and BD Diagnostics Sign Collaboration Agreement II-50
Lab21 Inks Partnership Agreement with a Major Pharmaceutical
Company II-51
Lab21 Signs Partnership Agreement with Leading IVD Company II-51
Lab21 and ITOR Establish Clinical Genomics Center II-51
Lab21 Takes over PCR Technology II-51
PerkinElmer and Macrogen Enter into Agreement II-51
NeoGenomics and Health Discovery Ink Exclusive Agreement for
Global Licensing II-51
QIAGEN Inks Agreement with Lepu Medical II-51
QIAGEN Inks Agreement with Bio-X Center II-51

9. FOCUS ON SELECT PLAYERS II-52
Abbott Molecular, Inc. (US) II-52
Affymetrix, Inc. (US) II-52
AstraZeneca plc (UK) II-52
Bayer HealthCare Pharmaceuticals (Germany) II-53
Beckman Coulter Genomics (US) II-54
bioMérieux SA (France) II-54
Clarient, Inc. (US) II-55
Dako Denmark A/S (Denmark) II-55
F. Hoffmann-La Roche Ltd. (Switzerland) II-56
GlaxoSmithKline plc. (UK) II-56
Hologic, Inc. (US) II-57
IRIS Personalized Medicine (US) II-57
Lab 21 Limited (UK) II-58
Macrogen, Inc. (Korea) II-58
QIAGEN NV (The Netherlands) II-59
Rosetta Genomics Ltd (Israel) II-60

10. GLOBAL MARKET PERSPECTIVE II-61
Table 20: World Recent Past, Current and Future Analysis for
Personalized Medicines by Geographic Region – US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2011 through 2020 (includes corresponding
Graph/Chart) II-61

Table 21: World 15-Year Perspective for Personalized Medicines
by Geographic Region – Percentage Breakdown of Revenues for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) II-62

Table 22: World Recent Past, Current and Future Analysis for
Targeted Therapeutics by Geographic Region – US, Canada,
Japan, Europe, Asia-Pacific and Rest of World Markets
Independently Analyzed with Annual Revenue Figures in US$
Million for Years 2011 through 2020 (includes corresponding
Graph/Chart) II-63

Table 23: World 15-Year Perspective for Targeted Therapeutics
by Geographic Region – Percentage Breakdown of Revenues for
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets for Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) II-64

Table 24: World Recent Past, Current and Future Analysis for
Tests & Lab Services for Personalized Medicine by Geographic
Region – US, Canada, Japan, Europe, Asia-Pacific and Rest of
World Markets Independently Analyzed with Annual Revenue
Figures in US$ Million for Years 2011 through 2020 (includes
corresponding Graph/Chart) II-65

Table 25: World 15-Year Perspective for Tests & Lab Services
for Personalized Medicine by Geographic Region – Percentage
Breakdown of Revenues for US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets for Years 2011, 2014
and 2020 (includes corresponding Graph/Chart) II-66


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
US Individualized Medicine Market to Witness Significant Growth III-1
Companies and Investors Bullish on Personalized Medicine
Market in the US III-1
Government Agencies Push for Personalized Medicines III-2
Personalized Medicine Regulations in the FDA – Changing for
the Better III-2
Challenges for FDA in Approving Personalized Drugs III-2
Increasing Burden of Chronic Diseases Drives Focus onto
Personalized Treatment III-3
Companion Diagnostic Market in the US III-3
Number of Companion Diagnostics under Development Keeps
Soaring III-4
Direct-to-Consumer Testing – A Growing Market III-4
Cancer Statistics in the US III-4
Table 26: New Cancer Cases by Gender and Affected Site in
the US (2013) III-5
Personalized Medicine Creating Opportunities for Diagnostics
Testing Services III-6
Molecular Diagnostics: Promising Growth Opportunities III-6
Genetic and Genomic Clinical Lab Testing Market: Promising
Prospects III-6
Product Launches/ Approvals III-8
Strategic Corporate Developments III-10
Select Players III-13
B.Market Analytics III-17
Table 27: The US Recent Past, Current and Future Analysis
for Personalized Medicines by Segment -Targeted Therapeutics
and Tests & Lab Services Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2011 through
2020 (includes corresponding Graph/Chart) III-17

Table 28: The US 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-18

2. CANADA III-19
A.Market Analysis III-19
Outlook III-19
Rising Incidence of Chronic Diseases Spurs Need for
Personalized Medicines III-19
Table 29: New Cancer Cases in Canada by Gender and Affected
Site (2012) (includes corresponding Graph/Chart) III-20

Table 30: New Cancer Cases in Canada by Province (2012)
(includes corresponding Graph/Chart) III-21

Table 31: New Cancer Cases in Canada by Age Group and
Gender (2012) (includes corresponding Graph/Chart) III-22
Strategic Corporate Development III-22
B.Market Analytics III-23
Table 32: Canadian Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-23

Table 33: Canadian 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-24

3. JAPAN III-25
A.Market Analysis III-25
Outlook III-25
Demographics Drive Market Growth III-25
Table 34: Percentage Breakdown of Japanese Population by
Age Group (2012) (includes corresponding Graph/Chart) III-25
Table 35: Over 65 Years Population in Japan (1950-2010)
(includes corresponding Graph/Chart) III-26
Product Approval III-26
B.Market Analytics III-27
Table 36: Japanese Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-27

Table 37: Japanese 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-28

4. EUROPE III-29
A.Market Analysis III-29
Outlook III-29
European Personalized Medicine Market to Exhibit Robust Growth III-29
Debt Crisis in Europe Affects Healthcare Industry III-29
European Healthcare System: In a State of Transition? III-30
Aging Population to Drive Demand for Personalized Medicines III-30
Table 38: Population Breakup by Age Group for Select
European Countries: 2012 (As a % of Total Population)
(includes corresponding Graph/Chart) III-31
Insight into Molecular Diagnostics Markets in Europe III-32
Table 39: Molecular Diagnostics Tests: Percentage Share
Breakdown by Function (includes corresponding Graph/Chart) III-32
Regulatory Scenario in Europe for Companion Diagnostics III-33
Companion Diagnostics: Select European Players with Strong
Biomarker Pipeline III-33
The Need for Improving Reimbursement Policies III-33
Product Approvals/Launches III-34
B.Market Analytics III-35
Table 40: European Recent Past, Current and Future Analysis
for Personalized Medicines by Geographic Region – France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-35

Table 41: European 15-Year Perspective for Personalized
Medicines by Geographic Region – Percentage Breakdown of
Revenues for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2011, 2014 and 2020 (includes
corresponding Graph/Chart) III-36

Table 42: European Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-37

Table 43: European 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-38

4a. FRANCE III-39
A.Market Analysis III-39
Outlook III-39
Biomérieux Sa – A Key Player III-39
B.Market Analytics III-40
Table 44: French Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-40

Table 45: French 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-41

4b. GERMANY III-42
A.Market Analysis III-42
Outlook III-42
Market Overview III-42
Strategic Corporate Development III-42
Bayer Healthcare Pharmaceuticals – A Key Player III-42
B.Market Analytics III-43
Table 46: German Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-43

Table 47: German 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-44

4c. ITALY III-45
Market Analysis III-45
Table 48: Italian Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-45

Table 49: Italian 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-46

4d. THE UNITED KINGDOM III-47
A.Market Analysis III-47
Outlook III-47
Initiatives Supporting the Personalized Medicine Market III-47
Product Approvals/Launches III-47
Strategic Corporate Developments III-48
Select Players III-49
B.Market Analytics III-51
Table 50: The UK Recent Past, Current and Future Analysis
for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-51

Table 51: The UK 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-52

4e. REST OF EUROPE III-53
A.Market Analysis III-53
Outlook III-53
Spain – Poised to become a Reckoning Force in Personalized
Medicines III-53
Strategic Corporate Development III-53
Select Players III-53
B.Market Analytics III-55
Table 52: Rest of Europe Recent Past, Current and Future
Analysis for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-55

Table 53: Rest of Europe 15-Year Perspective for
Personalized Medicines by Segment – Percentage Breakdown of
Revenues for Targeted Therapeutics and Tests & Lab Services
Markets for Years 2011, 2014 and 2020 (includes
corresponding Graph/Chart) III-56

5. ASIA-PACIFIC III-57
A.Market Analysis III-57
Outlook III-57
Healthcare Spending in Asia-Pacific: On the Rise III-57
China and India: Two Fast-Growing Markets III-57
Focus on Select Regions III-57
India III-57
Growing Investments in Pharmacogenomics Research Drives
Personalized Medicine in India III-57
Challenges Ahead III-58
China III-58
Government Support Drives Personalized Medicine Market in
China III-58
Product Launch III-59
Strategic Corporate Developments III-59
Macrogen, Inc. (Korea) – A Key Player III-59
B.Market Analytics III-60
Table 54: Asia-Pacific Recent Past, Current and Future
Analysis for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-60

Table 55: Asia-Pacific 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-61


6. REST OF WORLD III-62
A.Market Analysis III-62
Outlook III-62
Rosetta Genomics Ltd (Israel) – A Key Player III-62
B.Market Analytics III-63
Table 56: Rest of World Recent Past, Current and Future
Analysis for Personalized Medicines by Segment – Targeted
Therapeutics and Tests & Lab Services Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for
Years 2011 through 2020 (includes corresponding Graph/Chart) III-63

Table 57: Rest of World 15-Year Perspective for Personalized
Medicines by Segment – Percentage Breakdown of Revenues for
Targeted Therapeutics and Tests & Lab Services Markets for
Years 2011, 2014 and 2020 (includes corresponding
Graph/Chart) III-64



IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 85 (including Divisions/Subsidiaries – 93)

The United States (64)
Canada (2)
Japan (1)
Europe (20)
- France (5)
- Germany (5)
- The United Kingdom (6)
- Rest of Europe (6)
Asia-Pacific (Excluding Japan) (3)
Latin America (1)
Middle East (2)



Read the full report:
Global Personalized Medicines Industry

https://www.reportbuyer.com/product/2116899/Global-Personalized-Medicines-Industry.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


Source: PR Newswire



comments powered by Disqus